Sign In
Buy SMMT
$13.76
+0.715 (+5.48%)
At Close: Aug 04, 2026
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
07:00am, Wednesday, 05'th Aug 2026
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the expansion of its global registration-enabling clinical development program for the novel, potential first-in-class i
Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock
08:15am, Tuesday, 04'th Aug 2026
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying auto retailer Carvana Co. (NYSE:CVNA) on the heels of its “good” quarter.
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of “Hold” from Analysts
04:16am, Monday, 03'rd Aug 2026
Summit Therapeutics PLC (NASDAQ: SMMT - Get Free Report) has earned a consensus rating of "Hold" from the sixteen analysts that are presently covering the stock, Marketbeat.com reports. Two analysts h
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches
01:22pm, Friday, 31'st Jul 2026
Summit Therapeutics Inc. is upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, with a decision expected by November 14, 2026. SMMT's pivotal HARMONI study showed statistically sign
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm
08:52am, Monday, 27'th Jul 2026
NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) breached
Summit Therapeutics Flags Going Concern Risk Over Cash Needs
11:53am, Friday, 24'th Jul 2026
Summit Therapeutics Inc. (NASDAQ:SMMT) on Thursday reported an adjusted loss of 19 cents, better than the consensus loss of 28 cents per share.
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
10:11am, Friday, 24'th Jul 2026
Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
10:40pm, Thursday, 23'rd Jul 2026
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
Summit Therapeutics Q2 Earnings Call Highlights
06:07pm, Thursday, 23'rd Jul 2026
Summit Therapeutics NASDAQ: SMMT executives used the company's latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail t
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
04:05pm, Thursday, 23'rd Jul 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clini
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
11:36am, Thursday, 23'rd Jul 2026
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinat
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therap
Summit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data
03:31pm, Wednesday, 22'nd Jul 2026
Summit Therapeutics is upgraded from 'Hold' to 'Buy' following FDA acceptance of its BLA for ivonescimab + chemotherapy in EGFR-mutant NSCLC. SMMT's OS data in the HARMONi phase 3 trial improved over
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug
12:27pm, Wednesday, 22'nd Jul 2026
Summit Therapeutics Inc. (NASDAQ:SMMT) on Wednesday shared updated overall survival (OS) data from its Phase 3 HARMONi study, evaluating the investigational bispecific antibody ivonescimab for treatin
